Susan J. Connor
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Susan J. Connor has a total of 112 co-authors. Here are the top co-authors by number of shared publications:
- Miles Patrick Sparrow
Alfred Health and Monash University
8 shared publications - Sally Bell
St Vincent's Hospital, Melbourne, VIC
7 shared publications - Jane M. Andrews
Department of Gastroenterology and Hepatology, Royal Adelaide Hospital, Adelaide, South Australia, Australia
6 shared publications - Alissa J. Walsh
Translational Gastroenterology & Liver Unit, NIHR Oxford Biomedical Research Centre, Oxford University Hospitals NHS Foundation Trust, John Radcliffe Hospital
5 shared publications - Peter A. Bampton
Department of Gastroenterology and Hepatology, Flinders Medical Centre, South Australia, Australia; Flinders University of South Australia, Australia
5 shared publications - Graham L. Radford-Smith
Gastroenterology and Hepatology Department Inflammatory Bowel Disease Unit Royal Brisbane and Women's Hospital Brisbane Australia
4 shared publications
Latest Publications
- 1 May 2018
- Published by Elsevier in Gastroenterology
- Vol. 154 (6)
130 - In Fecal Microbiota Transplantation (FMT) for Ulcerative Colitis, Fusobacterium is Associated with Lack of Remission, while Metabolic Shifts to Starch Degradation and Short Chain Fatty Acid Production are Associated with Remission – Results from the Randomized Controlled Focus Study
- 1 May 2018
- Published by Elsevier in Gastroenterology
- Vol. 154 (6)
130 - In Fecal Microbiota Transplantation (FMT) for Ulcerative Colitis, Fusobacterium is Associated with Lack of Remission, while Metabolic Shifts to Starch Degradation and Short Chain Fatty Acid Production are Associated with Remission – Results from the Randomized Controlled Focus Study
- 1 May 2018
- Published by Elsevier in Gastroenterology
- Vol. 154 (6)
Tu1807 - Genetically Distinct Signatures of Mild and Severe Ulcerative Colitis
- 1 May 2018
- Published by Elsevier in Gastroenterology
- Vol. 154 (6)
Tu1807 - Genetically Distinct Signatures of Mild and Severe Ulcerative Colitis
- 1 May 2018
- Published by Elsevier in Gastroenterology
- Vol. 154 (6)
Mo1879 - Vedolizumab(VDZ) Real World Outcomes in Ulcerative Colitis (UC)
- 1 May 2018
- Published by Elsevier in Gastroenterology
- Vol. 154 (6)
Mo1879 - Vedolizumab(VDZ) Real World Outcomes in Ulcerative Colitis (UC)
- Open Access
- 29 August 2017
- Published by Springer Nature in BMC Medical Genetics
- Vol. 18 (1) , 1-11
Performance of risk prediction for inflammatory bowel disease based on genotyping platform and genomic risk score method
Predicting risk of disease from genotypes is being increasingly proposed for a variety of diagnostic and prognostic purposes. Genome-wide association studies (GWAS) have identified a large number of genome-wide significant susceptibility loci for Crohn’s disease (CD) and ulcerative colitis (UC), two subtypes of inflammatory bowel disease (IBD). Recent studies have demonstrated that including only loci that are significantly associated with disease in the prediction model has low predictive power and that power can substantially be improved using a polygenic approach. We performed a comprehensive analysis of risk prediction models using large case-control cohorts genotyped for 909,763 GWAS SNPs or 123,437 SNPs on the custom designed Immunochip using four prediction methods (polygenic score, best linear genomic prediction, elastic-net regularization and a Bayesian mixture model). We used the area under the curve (AUC) to assess prediction performance for discovery populations with different sample sizes and number of SNPs within cross-validation. On average, the Bayesian mixture approach had the best prediction performance. Using cross-validation we found little differences in prediction performance between GWAS and Immunochip, despite the GWAS array providing a 10 times larger effective genome-wide coverage. The prediction performance using Immunochip is largely due to the power of the initial GWAS for its marker selection and its low cost that enabled larger sample sizes. The predictive ability of the genomic risk score based on Immunochip was replicated in external data, with AUC of 0.75 for CD and 0.70 for UC. CD patients with higher risk scores demonstrated clinical characteristics typically associated with a more severe disease course including ileal location and earlier age at diagnosis. Our analyses demonstrate that the power of genomic risk prediction for IBD is mainly due to strongly associated SNPs with considerable effect sizes. Additional SNPs that are only tagged by high-density GWAS arrays and low or rare-variants over-represented in the high-density region on the Immunochip contribute little to prediction accuracy. Although a quantitative assessment of IBD risk for an individual is not currently possible, we show sufficient power of genomic risk scores to stratify IBD risk among individuals at diagnosis.
- 29 August 2017
- Published by Springer Nature in BMC Medical Genetics
- Vol. 18 (1) , 1-11
Open AccessPerformance of risk prediction for inflammatory bowel disease based on genotyping platform and genomic risk score method
Predicting risk of disease from genotypes is being increasingly proposed for a variety of diagnostic and prognostic purposes. Genome-wide association studies (GWAS) have identified a large number of genome-wide significant susceptibility loci for Crohn’s disease (CD) and ulcerative colitis (UC), two subtypes of inflammatory bowel disease (IBD). Recent studies have demonstrated that including only loci that are significantly associated with disease in the prediction model has low predictive power and that power can substantially be improved using a polygenic approach. We performed a comprehensive analysis of risk prediction models using large case-control cohorts genotyped for 909,763 GWAS SNPs or 123,437 SNPs on the custom designed Immunochip using four prediction methods (polygenic score, best linear genomic prediction, elastic-net regularization and a Bayesian mixture model). We used the area under the curve (AUC) to assess prediction performance for discovery populations with different sample sizes and number of SNPs within cross-validation. On average, the Bayesian mixture approach had the best prediction performance. Using cross-validation we found little differences in prediction performance between GWAS and Immunochip, despite the GWAS array providing a 10 times larger effective genome-wide coverage. The prediction performance using Immunochip is largely due to the power of the initial GWAS for its marker selection and its low cost that enabled larger sample sizes. The predictive ability of the genomic risk score based on Immunochip was replicated in external data, with AUC of 0.75 for CD and 0.70 for UC. CD patients with higher risk scores demonstrated clinical characteristics typically associated with a more severe disease course including ileal location and earlier age at diagnosis. Our analyses demonstrate that the power of genomic risk prediction for IBD is mainly due to strongly associated SNPs with considerable effect sizes. Additional SNPs that are only tagged by high-density GWAS arrays and low or rare-variants over-represented in the high-density region on the Immunochip contribute little to prediction accuracy. Although a quantitative assessment of IBD risk for an individual is not currently possible, we show sufficient power of genomic risk scores to stratify IBD risk among individuals at diagnosis.
- 6 June 2016
- Published by Wiley in Journal of Gastroenterology and Hepatology
- Vol. 31, 8-9
Biologic Therapeutic Drug Monitoring in Australia
- 6 June 2016
- Published by Wiley in Journal of Gastroenterology and Hepatology
- Vol. 31, 8-9
Biologic Therapeutic Drug Monitoring in Australia
- 1 April 2016
- Published by Elsevier in Gastroenterology
- Vol. 150 (4) , S564-S565
Su1831 Identifying “At Risk” Inflammatory Bowel Disease Patients Who May Be Targeted With a New Adjuvanted Herpes Zoster Subunit Vaccine
- 1 April 2016
- Published by Elsevier in Gastroenterology
- Vol. 150 (4) , S564-S565
Su1831 Identifying “At Risk” Inflammatory Bowel Disease Patients Who May Be Targeted With a New Adjuvanted Herpes Zoster Subunit Vaccine
- 7 March 2016
- Published by Wiley in Internal Medicine Journal
- Vol. 46 (5) , 590-595
Faecal calprotectin: current usage and perceived beneficial effects of third-party funding on rates of colonoscopy by Australian gastroenterologists
- 7 March 2016
- Published by Wiley in Internal Medicine Journal
- Vol. 46 (5) , 590-595
Faecal calprotectin: current usage and perceived beneficial effects of third-party funding on rates of colonoscopy by Australian gastroenterologists
- 1 July 2014
- Published by Elsevier in Diabetes Research and Clinical Practice
- Vol. 105 (1) , e6-e8
Acute renal failure and metformin-associated lactic acidosis following colonoscopy
- 1 July 2014
- Published by Elsevier in Diabetes Research and Clinical Practice
- Vol. 105 (1) , e6-e8
Acute renal failure and metformin-associated lactic acidosis following colonoscopy